Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23544076 | 0.79 | MEN1 (0.38) | ALDH1A1KMT2ALMNAMEN1HPGD | |
| SCHEMBL3799434 | 0.79 | MCHR1 (0.44) | ALDH1A1KMT2ALMNAMEN1HPGD | |
| SCHEMBL3796715 | 0.79 | ADORA3 (0.49) | ALDH1A1KMT2AMEN1CYP2A6KDM4E | |
| SCHEMBL3789440 | 0.79 | MEN1 (0.41) | ALDH1A1KMT2ALMNAMEN1HPGD | |
| SCHEMBL16632584 | 0.78 | SLC6A4 (0.48) | ALDH1A1KMT2ALMNAMEN1HPGD | |
| SCHEMBL3789397 | 0.76 | MCHR1 (0.46) | CYP2A6CA9 | |
| SCHEMBL15495778 | 0.76 | ADORA2A (0.54) | ALDH1A1KMT2ALMNAMEN1HPGD | |
| SCHEMBL3795511 | 0.74 | MCHR1 (0.48) | — | |
| SCHEMBL30879595 | 0.73 | CYP1A2 (0.51) | ALDH1A1KMT2ALMNAMEN1HPGD | |
| SCHEMBL27499528 | 0.73 | CYP1A2 (0.51) | ALDH1A1KMT2ALMNAMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930620-A | Tetrafused ring compound, preparation method, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| EP-4358954-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-112041296-B | Aminoacetamides containing benzooxy alicyclic structures and uses thereof | 上海璃道医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| CN-114761410-B | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20230159766-A1 | CONDUCTIVE POLYMER COMPOSITION, SUBSTRATE, AND METHOD FOR PRODUCING SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-0152340-B1 | 2-Sulfamoylbenzo[b]furan derivatives and ophtalmic composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4758676-A | Intermediates for antiatherosclerotic furochromones | THE UPJOHN COMPANY (US) | 1988-07-19 | — | — | US | disclosed |
| US-4623737-A | Synthesis of precursors of anti-atherosclerotic furochromones | THE UPJOHN COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
| US-4579865-A | ANTIISCHEMIC, HYPOGLYCEMIC AGENTS | USV PHARMACEUTICAL CORP. (US) | 1986-04-01 | — | — | US | disclosed |
| US-4576632-A | HERBICIDES, PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4544667-A | CARBONIC ANHYDRASE INHIBITOR; VISION DEFECTS | MERCK & CO., INC. (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0152340-A1 | 2-Sulfamoylbenzo[b]furan derivatives and ophtalmic composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1985-08-21 | — | — | EP | disclosed |
| US-4494979-A | HERBICIDES;PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0116938-A1 | Benzoheterocyclic carbamates | USV PHARMACEUTICAL CORPORATION (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0071441-A2 | Benzofuran sulfamates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | ALDH1A1 3716/4885KMT2A 1017/4885LMNA 1270/4885 |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | ALDH1A1 3716/4885KMT2A 1017/4885LMNA 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.